Note: This is NOT an IPO. This is a Direct Listing by Polaryx Therapeutics (PLYX Proposed) on the NASDAQ. Maxim Group is the financial advisor for this Direct Listing.

(Incorporated in Nevada)

We are a clinical-stage biotechnology company developing novel therapies for rare pediatric lysosomal storage disorders (LSDs).

In the first half of 2026, we intend to launch SOTERIA, a single-arm open-label Phase 2 basket trial evaluating our lead drug candidate, PLX-200, for multiple LSD indications. 

(Note: Polaryx Therapeutics shares started trading at $45.00 in their NASDAQ Direct Listing debut at 11:10 a.m. EST on Monday, Feb. 2, 2026, and 958 shares traded at that price, according to NASDAQTrader.com – resulting in $43,110.00 in dollar volume on that first trade. Polaryx Therapeutics shares closed at $35.00 on volume for the day of 25,292 shares on Monday, Feb. 2, 2026, the company’s first day of trading on NASDAQ as the result of its Direct Listing, according to NASDAQ. The stock traded from a low of $20.00 to an intraday high of $48.91 on Monday, Feb. 2, 2026.)

(Background: Polaryx Therapeutics disclosed plans to list up to 47.34 million shares (47,343,297 shares) in a NASDAQ  Direct Listing, according to its S-1/A filing in late January 2026. A reference price was not disclosed. In the prospectus, Polaryx Therapeutics said that in September 2025 and through the date of this prospectus, the company had issued an aggregate of 471,469 shares of common stock to investors at an average price per share of $2.51.)